Dr. Mary Katherine Samplaski, MD

Dr. Samplaski practices at K and B Surgical Center, LLC in Beverly Hills, California.

Dr. Samplaski's NPI, 1093985756, was assigned on March 8, 2008. Dr. Samplaski graduated from George Washington University School of Medicine and Health Sciences in 2005. Dr. Samplaski holds California license A131958.

Dr. Samplaski's primary practice is K and B Surgical Center, LLC, at 9033 Wilshire Blvd, Beverly Hills, CA 90211 in Los Angeles County. The practice phone is (310) 858-1242.

Dr. Samplaski's primary practice is K and B Surgical Center, LLC in Beverly Hills, California. The medical group on file is USC Care Medical Group. Dmand AI also links Dr. Samplaski to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Samplaski practices. Vendor and product names are available with a free account.

Urology is Dr. Samplaski's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Samplaski is board certified in urology by the American Board of Urology. Dmand AI has Dr. Samplaski's licenses on file in 3 states: California, Florida and Ohio.

Dmand AI lists bladder disease, enlarged prostate, erectile dysfunction, kidney cysts, kidney stone disease, testicular dysfunction, urinary endoscopy and UTI among the conditions Dr. Samplaski treats.

CMS data shows 191 Medicare services from Dr. Samplaski across 3 procedure codes in 2024, all of them office visits, for 125 Medicare patients. Medicare paid $13,034 for them.

CMS counts 125 Medicare patients who saw Dr. Samplaski in 2024. The largest group is 65 to 74, with 62 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 34% are also on Medicaid. Their average risk score is 1.59, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Samplaski's median patient age at 47, with 12% women.

In 2024, Dr. Samplaski wrote 493 Medicare Part D claims for 91 patients. 85% of them were for generic drugs. CMS names the drug for 369 of them, across 15 drugs with 11 or more claims each, at $50,723 in total drug cost. In 2023, CMS named 282 claims across 12 drugs.

Dmand AI links 51 papers to Dr. Samplaski, published from 2003 to 2024. 2020 was the busiest year, with 6. The most frequent topics are Infertility, Male, Semen Analysis and Fertility. Dr. Samplaski has published most often in Fertil Steril. Dr. Samplaski's most frequent co-authors are James F. Smith, MD, Tung-Chin Hsieh, MD and Edmund Yuey Kun Ko, MD.

CMS Open Payments shows 22 general payments to Dr. Samplaski from 14 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 99% of the total. NeoTract Inc. paid the most, $161.

Dmand AI lists 2 awards for Dr. Samplaski, most recently Member in 2015.

Dr. Samplaski graduated from George Washington University School of Medicine and Health Sciences in 2005. Dr. Samplaski is a member of AUA.

Dr. Samplaski is in network with 14 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.